Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Telaglenastat · CB-839

Small molecule · Inhibitor of glutaminase (GLS) · developed by Calithera Biosciences

Phase 2 Most advanced trial (none active)

What is Telaglenastat?

Telaglenastat (CB-839) is an orally bioavailable small molecule that selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that converts glutamine into glutamate. By blocking glutamine utilization, it impairs proliferation of rapidly growing, glutamine-dependent cells. It is studied in metastatic prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CB-839
Drug type
Small molecule
Targets
glutaminase (GLS)
Mechanism
Inhibitor of glutaminase (GLS)
Pathways
glutamine metabolism, conversion of glutamine to glutamate
Therapy area
Oncology
Developer
Calithera Biosciences, Inc
In trials of
PFE
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
U6CL98GLP4

Conditions studied

Prostate Cancer Metastatic

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.